Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Titel:
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Auteur:
Shapiro, Jeremy D. Thavaneswaran, Subotheni Underhill, Craig R. Robledo, Kristy P. Karapetis, Christos S. Day, Fiona L. Nott, Louise M. Jefford, Michael Chantrill, Lorraine A. Pavlakis, Nick Tebbutt, Niall C. Price, Timothy. J. Khasraw, Mustafa Van Hazel, Guy A. Waring, Paul M. Tejpar, Sabine Simes, John Gebski, Val J. Desai, Jayesh Segelov, Eva